Literature DB >> 20518069

Mitotic drug targets.

Phillip Kaestner1, Holger Bastians.   

Abstract

Mitosis is the key event of the cell cycle during which the sister chromatids are segregated onto two daughter cells. It is well established that abrogation of the normal mitotic progression is a highly efficient concept for anti-cancer treatment. In fact, various drugs that target microtubules and thus interfere with the function of the mitotic spindle are in clinical use for the treatment of various human malignancies for many years. However, since microtubule inhibitors not only target proliferating cells severe side effects limit their use. Therefore, the identification of novel mitotic drug targets other than microtubules have gained recently much attention. This review will summarize the latest developments on the identification and clinical evaluation of novel mitotic drug targets and will introduce novel concepts for chemotherapy that are based on recent progress in our understanding how mitotic progression is regulated and how anti-mitotic drugs induce tumor cell death.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20518069     DOI: 10.1002/jcb.22721

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  15 in total

1.  Up-regulation of pro-apoptotic protein Bim and down-regulation of anti-apoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor.

Authors:  Takumi Kawabata; Susumu Tanimura; Kohei Asai; Ryohei Kawasaki; Yumi Matsumaru; Michiaki Kohno
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

Review 2.  Mitosis as an anti-cancer drug target.

Authors:  Anna-Leena Salmela; Marko J Kallio
Journal:  Chromosoma       Date:  2013-06-18       Impact factor: 4.316

3.  Clinicopathological relevance of kinesin family member 18A expression in invasive breast cancer.

Authors:  Mai Kasahara; Makoto Nagahara; Tsuyoshi Nakagawa; Toshiaki Ishikawa; Takanobu Sato; Hiroyuki Uetake; Kenichi Sugihara
Journal:  Oncol Lett       Date:  2016-07-07       Impact factor: 2.967

Review 4.  Killing cells by targeting mitosis.

Authors:  E Manchado; M Guillamot; M Malumbres
Journal:  Cell Death Differ       Date:  2012-01-06       Impact factor: 15.828

5.  Discovery and Optimization of Seven-Membered Lactam-Based Compounds to Phenocopy the Inhibition of the Aurora Kinase B.

Authors:  Jian Huang; Qiong Shi; Namrta Choudhry; Hongmei Li; Chenglu Yang; Julia Kalashova; Ziqi Yan; Jinhua Li; Mallu Chenna Reddy; Sridhar Goud Gopala; Shenqiu Zhang; Jing Zhang; Naganna Nimishetti; Dun Yang
Journal:  ACS Med Chem Lett       Date:  2022-06-06       Impact factor: 4.632

Review 6.  Targeting tumour-supportive cellular machineries in anticancer drug development.

Authors:  Matthias Dobbelstein; Ute Moll
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

7.  Mitotic control of cancer stem cells.

Authors:  Monica Venere; Tyler E Miller; Jeremy N Rich
Journal:  Cancer Discov       Date:  2013-02       Impact factor: 39.397

8.  BUB1 and BUBR1 inhibition decreases proliferation and colony formation, and enhances radiation sensitivity in pediatric glioblastoma cells.

Authors:  Andressa Gois Morales; Julia Alejandra Pezuk; María Sol Brassesco; Jaqueline Carvalho de Oliveira; Rosane Gomes de Paula Queiroz; Hélio Rubens Machado; Carlos Gilberto Carlotti; Luciano Neder; Harley Francisco de Oliveira; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  Childs Nerv Syst       Date:  2013-06-02       Impact factor: 1.475

9.  Defective cell cycle checkpoints as targets for anti-cancer therapies.

Authors:  Brian Gabrielli; Kelly Brooks; Sandra Pavey
Journal:  Front Pharmacol       Date:  2012-02-02       Impact factor: 5.810

Review 10.  Mechanisms by Which Kinesin-5 Motors Perform Their Multiple Intracellular Functions.

Authors:  Himanshu Pandey; Mary Popov; Alina Goldstein-Levitin; Larisa Gheber
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.